Fulcrum Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Fulcrum Therapeutics Inc FULC.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of five analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -35 cents to -23 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Fulcrum Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $17.66 million.

• Fulcrum Therapeutics Inc shares had risen by 33.7% this quarter and lost 18.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 19.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00

This summary was machine generated from LSEG data May 1 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)